Drug utilization of clarithromycin for gastrointestinal disease treatment

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 39

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Oct 21, 2008; 14(39): 6065-6071
Published online Oct 21, 2008. doi: 10.3748/wjg.14.6065

Table 4 CYP3A based clinical significant drug interactions with clarithromycin

Concurrent medications primarily metabolized by CYP3A	Clarithromycin		References
Concurrent medications primarily metabolized by CYP3A	SR	IR	References
Alprazolam and zolpidem	1		[6,7]
Midazolam	1		[6,8]
Amlodipine	1	2	[9]
Levoamlodipine		1
Nifedipine		1	[10]
Carbamazepine		1	[11]
Nifedipine, clopidogrel and atorvastatin		1	[10,12-14]
Amlodipine and ergoloid mesylate sustained release capsules		1	[9,15]
Prednisone		1	[16]

SR: Sustained-release; IR: Immediate release.

Citation: Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071
URL: https://www.wjgnet.com/1007-9327/full/v14/i39/6065.htm
DOI: https://dx.doi.org/10.3748/wjg.14.6065

Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071 [PMID: 18932287 DOI: 10.3748/wjg.14.6065]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.